Member Info for LovableLumax

Are you serious? Less than £9k of buys FFS. Yeah MMs playing games, funny as.

If you were unable to work out that sells were 100p and buys a little less than 100.2p then you could’ve put a dummy buy through. I think for most it wouldn’t be necessary as was obvious and wouldn’t take a working day let alone life in the markets to work it out!

In the market all your working life and you needed someone else to inform you what the spread was? I assume your journey up the corporate ladder was brief?!

If you're unable to work it out alarm bells should be ringing.

Yeah I saw that gmcc which further illustrates Fiona was gently pushed. If she was leaving of her own accord and had a full time role in mind she wouldn’t be taking a NED role on.

Fiona is stepping down as her role is encompassed in Chris’. We have evolved as a business and the clinic is now all important which is the development element of R&D.

It’s not as if Fiona is leaving to pursue other opportunities which is always the quote given when it’s someone’s choice to leave.

Appointment marks the transition from a research organization to a clinical stage biotechnology company

Heights and fair play as no share price damage so brokers doing their job.

Agreed and I’d say Jive Turkey absolutely top notch.

Let’s hope we have again bounced off the low end of the range and can regain momentum ahead of some positive RNSs.

Ian it’s the nature of the beast. What I find funny is someone taking short positions when they can’t read basic RNSs or understand cash burn. Pretty fundamental.

It’s cash burn FFS. We pay Heights in shares, around 50k a day each quarter.

Trendz, you don’t have a ‘specific methodology’ you are relying on a broker note that likely includes depreciation, amortisation. Best to look at recent cash burn.

Funny you are happy to rely on parts of the broker note that suit your position. What’s their valuation?

Trendz it’s simple. Look at their cash as at Dec 31 2022 and look at the cash position June 30 2023 and you will see they burnt less than £9m. They ended 2022 with £41.8m and bought Coris for £7.4m. They had £26m at June 30 so burnt £8.4m in 6 months.

I suspect they have a plan that will be public soon enough. I doubt the recent appointees would have joined full time roles without being told finance to be secured.

*As I said H1 23 cash burn under £1.5m/month.

So you lay attention to their forecasts on financials but not valuation? I suggest you look at previous ARs and IRs to give you a sense of cash burn. As I said H2 23 cash burn under £1.5m/month.

You have a short so I guess will continue to push your narrative but at least you’re honest.

Agreed. Affimers need to be retained for TX but can license for DX . A large number of papers written on affimers as a better alternative to antibodies.

https://avacta.com/about/scientific-resources/

*your short precarious

Trendz, you are relying on a broker note. Tell me what is the broker’s valuation?

Am I wrong when I say the historical burn is around £1.5m/month. Also I expect DX to contribute cash, only a little but it helps.

You’re short precarious. We are in the lower end of our range (circa 100-140p) but the next month or so will be key and determine if you’re quids in or badly burnt.

At least trendz admits a short rather than people posting on here incessantly apparently without a position.

Trends is relying on broker notes. If that’s the case what is the broker’s valuation of Avacta?

You should look at cash burn FY22 or indeed H123 and you will see they only burnt

H2 23 they burnt £8.4m (Coris acquisition was £7.4m).

They have cash until the back end of the year. They will strengthen the balance sheet shortly and if it’s a raise it won’t include retail but IIs although I suspect licensing deal TBA soon.